These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2009-009315-22 A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study) bad-data
Ongoing 2010-022104-50 A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT12 not-yet-due
Ongoing 2012-005272-34 Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment. Het opnieuw geven van Iressa in EGFR-gemuteerde patienten die ree... not-yet-due
Ongoing 2012-005834-12 Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase ... not-yet-due
Ongoing 2013-002050-78 A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced nonsmall cell lung cancer not-yet-due
Ongoing 2013-004303-39 A randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT17 study not-yet-due
Listed as ongoing, but also has a completion date 2013-004324-11 Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15 st... 2019-01-15 bad-data
Ongoing 2015-003121-34 Chemotherapy in KRAS mutated chemotherapy naive non-small cell lung cancer patients: a phase III study comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 not-yet-due
Ongoing 2018-001781-41 Evaluation of safety and tolerability of pirfenidone in asbestosis, a multicenter study Evaluatie van de veiligheid en tolerantie van Pirfenidone bij asbestose, een multicenter studie not-yet-due